Roger E. McLendon

Duke University

Public scientific profile · Unclaimed

Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.

Top expertise

  • Glioma Diagnosis and Treatment

    Strong evidence · 4 supporting papers · latest 2026

  • Telomeres, Telomerase, and Senescence

    Strong evidence · 1 supporting paper · latest 2026

  • Cancer Immunotherapy and Biomarkers

    Strong evidence · 1 supporting paper · latest 2025

  • Cell Adhesion Molecules Research

    Strong evidence · 1 supporting paper · latest 2025

  • Radiomics and Machine Learning in Medical Imaging

    Solid evidence · 2 supporting papers · latest 2026

  • Immune cells in cancer

    Solid evidence · 2 supporting papers · latest 2026

  • Ferroptosis and cancer prognosis

    Solid evidence · 2 supporting papers · latest 2026

  • Single-cell and spatial transcriptomics

    Solid evidence · 2 supporting papers · latest 2026

Publications (7)

  • A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma

    2025DOIPMID 41131134

  • KS03.4.A SPATIAL MULTI-OMIC PROFILING REVEALS DETERMINANTS OF TIL EXPANDABILITY IN HIGH-GRADE GLIOMAS

    2025DOI

  • SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres

    2026DOIPMID 41520142

  • BIOM-89. PI3K PATHWAY ALTERATIONS ARE DRIVERS OF PROGRESSION AND PREDICT WORSE OVERALL SURVIVAL IN NEWLY DIAGNOSED MOLECULARLY-DEFINED OLIGODENDROGLIOMA

    2025DOI

  • BIOM-72. INTEGRATIVE SINGLE-NUCLEI SPATIAL TRANSCRIPTOMIC PROFILING OF PRIMARY AND RECURRENT HUMAN IDH-WILDTYPE GLIOBLASTOMA REVEALS CELL-SPECIFIC EGFRVIII EXPRESSION AND ANXA1 SIGNALING AXIS

    2025DOI

  • Abstract 1293: A multimodal AI framework integrating spatial omics and radiomics for recurrence prediction in glioblastoma.

    2026DOI

  • Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma

    2026DOIPMID 42040926

Organizations in sourced records

Affiliation evidence only — not confirmed current employment.

  • Duke University

Source: OpenAlex · retrieved 2026-09-29

Are you Roger E. McLendon? Sign in to claim this profile